Retatrutide fully resolves sleep apnea for up to 25% of trial patients in NEJM TRIUMPH trials

In the NEJM TRIUMPH trials, the investigational triple agonist retatrutide fully resolved sleep apnea for up to 25% of clinical trial patients, cutting sleep apnea events by 30+ per hour and putting roughly 1 in 4 non-diabetic patients into full remission at the lowest dose.

Detected & updated continuously · Source: Nebula